We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
9.50 | 0.58% | 1,645.50 | 1,645.00 | 1,645.50 | 1,650.00 | 1,635.00 | 1,642.00 | 520,680 | 09:21:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.71 | 67.54B |
Date | Subject | Author | Discuss |
---|---|---|---|
06/10/2022 20:28 | The guy is a penniless dolt-spends his jobless days on ADVFN trolling various boards. Filtered the loser ages ago. | cumnor | |
06/10/2022 19:39 | Jeepers TM nobody knows the full extent of the Zantac litigation and which companies will get hit with legal costs. As for cashflow 9 billion shares 1.8p or 3.6p assuming 100% payout, 50% payout yield just 1.8p per share that is terrible!!! | paul planet earth | |
06/10/2022 11:10 | PPE is just a troll and not worth the effort indulging.. | rikky72 | |
06/10/2022 10:22 | GSK dividends in my accounts this morning (thx to AJ Bell) | tradermichael | |
06/10/2022 08:56 | PPE, I think you are overreacting. Haleon has said it had rejected indemnification requests from GSK and Pfizer “on the basis that the scope of the indemnities set out in the joint venture agreement only covers their consumer healthcare businesses as conducted when the JV was formed in 2018”. It added: “At that time, neither GSK nor Pfizer marketed [over the counter] Zantac in the US or Canada.” Litigation surrounding Zantac, which was previously marketed by GSK and Pfizer is a distraction, but Haleon itself never marketed this product and significant financial costs are not anticipated, other than those of defending the litigation, being incurred by Haleon as a result. And on cash flow, the group expects continued growth in the second half of the year, albeit not at such a strong pace. Cash flow was especially strong, with the group delivering free cash flow of over £550m in the half-year, compared to £364m at the 2021 half-year stage. With strong cash flows, Haleon should rapidly deleverage, which will help to drive financial returns higher, over and above the growth from the brands portfolio. Haleon should have excellent dividend growth potential over the longer term as a result. | tradermichael | |
06/10/2022 08:21 | Doubt it GSK and Pfizer will start dumping come November afterall you've got a multi billion dollar Zantac law suite to fund. Why hold Haleon shares that generate f@@kall cash flow! | paul planet earth | |
06/10/2022 08:01 | Feel free to dump your shares Paul , wiser to keep them though | alibizzle | |
06/10/2022 07:48 | Haleon H2 results EPS 9p a share so 3p to 4.5p dividend payout to GSK investors..better dumping those shares at 270p not even a 2% share holder yield!..Most of their free cash flow used up servicing £8 billion debt ffs and that's at just 2.8% f@@k knows how they will cope as interest rates rise and find debt reduction is harder to achieve, higher inflation, rising cost base, consumers cutting spending and switching to generic cheaper rivals brands! | paul planet earth | |
06/10/2022 07:31 | PPE: In its H1 earnings report, Haleon expected the initial dividend to be at the lower end of a 30%-50% pay-out ratio, subject to board approval. | tradermichael | |
05/10/2022 08:53 | Glaxo Wellcome (GW) and SmithKline Beecham (SB) joined forces at the end of 2000. The £114 billion merger created a giant with an estimated global market share of 7% of the world pharmaceutical market. In over 20 years since then, how much has the company added value to the business? | tradermichael | |
04/10/2022 19:20 | Thats alot of shares to dump especially as Halitosis told both Pfizer and GSK to get stuffed regarding the Zantac indemnities. | paul planet earth | |
04/10/2022 09:07 | Still a lot of dust in the air until after the options to sell in November following the 'lock-up' period .... (Pfizer, 32%, GSK 6%) | tradermichael | |
04/10/2022 08:38 | Any views on the Halitosis IPO sell off..was it a good or bad move by the GSK board in light of Unlevers original offer now the dust has settled? | paul planet earth | |
03/10/2022 08:48 | Stopped updating price on GSK website | jonjoneil | |
03/10/2022 08:02 | ....and there's sub 13! | spoole5 | |
01/10/2022 13:29 | Thanks Michael . | alibizzle | |
01/10/2022 08:09 | “Haleon expects to pay a dividend to Haleon shareholders in relation to the second half of 2022 in the first half of 2023, subject to Haleon Board approval and following approval of Haleon's FY22 results.” | tradermichael | |
30/9/2022 19:52 | When does haleon divided pay out ? | alibizzle | |
30/9/2022 15:54 | 16.25p dividend pays out next Thursday .... ;0) | tradermichael | |
29/9/2022 16:01 | Porsche is just a sad troll . Yawn | alibizzle | |
29/9/2022 15:15 | Porsche1945. Filtered | tday | |
29/9/2022 12:28 | Looks like the brexit loony Tory basket cases that ubs just described as akin to a death wish cult, have finally managed to blow up the U.K. once and for all. Gsk of course with another load of problems on top all of its own. | porsche1945 | |
29/9/2022 09:45 | 1815p last April, 1815p next April! | tradermichael |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions